ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "giant cell arteritis"

  • Abstract Number: 1419 • ACR Convergence 2021

    Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis

    Mwidimi Ndosi1, Celia Almeida2, Jill Dawson3, Emma Dures2, Rosemary Greenwood4, Catherine Guly5, Sarah Mackie6, Alison Bromhead4, Steve Stern4 and Joanna Robson2, 1University of the West of England, Bristol, Filton, United Kingdom, 2UWE Bristol, Bristol, United Kingdom, 3University of Oxford, Oxford, 4University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, 5University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, 6School of Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA) causes inflammation of the blood vessels of the head and neck and can cause visual loss and large vessel vasculitis.…
  • Abstract Number: 0503 • ACR Convergence 2021

    18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis

    Kaitlin Quinn1, Mark A. Ahlman2, Hugh Alessi3, Ashkan Malayeri2, Jamie Marko2, Elaine Novakovich2 and Peter Grayson4, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2National Institutes of Health, Bethesda, MD, 3National Institutes of Health, Bethesda, Maryland, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
  • Abstract Number: 1403 • ACR Convergence 2021

    Giant Cell Arteritis Subtypes: Data from the ARTESER Registry

    Eugenio De Miguel1, Jesús T. Sánchez-Costa2, Javier Narvaez3, Miguel Ángel gonzalez-Gay4, Noemí Garrido-Puñal5, Paula V. Estrada-Alarcon6, Rafael B. Melero-González7, Elisa Fernández-Fernández8, María T. Silva-Diaz9, Joaquín M. Belzunegui10, Clara Moriano11, Julio Sánchez12, Judit Lluch13, Itziar Calvo14, Vicente Aldasoro15, Leticia León-Mateos16, Javier Loricera García17, Alberto Ruíz-Román5, Cristina Valero-Martínez18, Patricia Moya19, Marina Tortosa-Cabañas20, Vanessa A. Navarro-Angeles6, Carles Galisteo21, Anne Riveros-Frutos22, Jose A. Román-Ivorra23, Selene Labrada-Arrabal24, Margarida Vasques-Rocha25, Carlota L. Iñiguez-Ubiaga26, María García-González27 and Ricardo Blanco28, 1Hospital Universitario La Paz, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Virgen del Rocío, Sevilla, Spain, 6Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 7Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 8Rheumatology department, La Paz University Hospital, Madrid, Spain, 9Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 10Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 11Hospital Universitario de León, León, Spain, 12Hospital Universitario 12 de Octubre, Madrid, Spain, 13Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Complejo Hospitalario de Navarra, Pamplona, Spain, 16Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 17Hospital Universitario Marqués de Valdecilla, Santander, Spain, 18Hospital Universitario de La Princesa, Madrid, Spain, 19Hospital Sant Pau, Barcelona, Spain, 20Hospital Universitario Ramón y Cajal, Madrid, Spain, 21Hospital Universitari Parc Tauli, Saadell, Spain, 22Hospital Germans Trias i Pujol, Badalona, Spain, 23Hospital Universitari i Politècnic La Fe, Valencia, Spain, 24Hospital del Mar, Barcelona, Spain, 25Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 26Hospital Universitario Lucus Augusti, Lugo, Spain, 27Hospital Universitario de Canarias, La Laguna, Spain, 28Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis over 50 years of age. Classically, GCA was assimilated with the involvement of the…
  • Abstract Number: 1859 • ACR Convergence 2021

    Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study

    Adam Geressu1 and Marwan Bukhari2, 1Royal Lancaster Infirmary, Lancaster, United Kingdom, 2British Society for Rheumatology, London, United Kingdom

    Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…
  • Abstract Number: 0505 • ACR Convergence 2021

    Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States

    Despina Michailidou1, Tianyu Zhang2, Pavlos Stamatis3 and Bernard Ng4, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Biostatistics, University of Washington, Seattle, WA, 3Lund University, Lund, Sweden, 4Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA

    Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
  • Abstract Number: 1404 • ACR Convergence 2021

    Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis; A Population-based Study

    jigisha rakholiya1, Mohanad Elfishawi1, Tina Gunderson1, Cynthia Crowson2, Eric Matteson3, Carl Turesson4, Karin Wadström5, Cornelia Weyand1, Matthew Koster1 and Kenneth Warrington6, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN, 3Mayo Clinic College of Medicine and Science, Rochester, MN, 4Lund University, Malm, Sweden, 5Lund University, Malmö, Sweden, 6Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Advancing age, female sex and white race are well-known risk factors for development of giant cell arteritis (GCA). Recent studies suggest that certain metabolic…
  • Abstract Number: 1862 • ACR Convergence 2021

    Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis

    Kristina Wells1, Fernanda Gutierrez-Rodrigues2, Bhavisha Patel2, Kaitlin Quinn3, Keith Sikora1, Neal Young4 and Peter Grayson5, 1National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 4National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…
  • Abstract Number: 0506 • ACR Convergence 2021

    Transcriptomic Changes Induced by Mavrilimumab versus Tocilizumab in ex-vivo Cultured Arteries from Patients with Giant-cell Arteritis

    Marc Corbera- Bellalta1, Farah Kamberovic1, Farran Araujo2, Roser Alba-Rovira1, Georgina Espigol-Frigolé1, Marco A. Alba1, Sergio Prieto-Gonzalez1, José Hernández-Rodríguez1, Patricia Pérez-Galán2, Alexandra Joseph3, John F Paolini3 and Maria C. Cid1, 1Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, 2Department of Hemato-Oncology (IDIBAPS), Barcelona, Spain, 3Kiniksa Pharmaceuticals Corp., Lexington, MA

    Background/Purpose: Giant cell arteritis (GCA) is a chronic disease, and affected patients suffer from relapses and glucocorticoid (GC)-related toxicity. Targeted therapies are emerging with the…
  • Abstract Number: 1405 • ACR Convergence 2021

    Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases

    Lara Sánchez-Bilbao1, Javier Loricera1, Santos Castañeda2, Clara Moriano3, Javier Narvaez4, Vicente Aldasoro5, Olga Maíz6, Rafael Melero7, Juan Ignacio Villa8, Paloma Vela9, Susana Romero-Yuste10, José Luis Callejas11, Eugenio De Miguel12, Eva Galindez-Agirregoikoa13, Francisca Sivera14, Jesús Carlos Fernández-López15, Carles Galisteo16, Iván Ferraz-Amaro17, Juan Carlos Nieto18, Juan Ramón de Dios19, Julio Sánchez20, Esther Fernández21, Isabel de la Morena22, Patricia Moya23, Roser Solans-Laqué24, Jose Luis Andreu25, Marcelino Revenga26, Eztizen Labrador27, Andrea García-Valle28, Adela Gallego29, Carlota Iñíguez30, Cristina Hidalgo31, Noemí Garrido-Puñal32, Ruth López-González33, José Andrés Román-Ivorra34, Sara Manrique Arija35, Paz Collado36, Enrique Raya11, Francisco Navarro37, Antoni Juan Mas38, Carmen Ordas39, Maria Dolors Boquet40, Noelia Álvarez-Rivas41, Maria Luisa Velloso-Feijoo42, Cristina Campos-Fernández43, Íñigo Rúa-Figueroa44, Arantxa Conesa45, Eva Salgado46, Miguel Ángel gonzalez-Gay47 and Ricardo Blanco48, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario de la Princesa, Madrid, Spain, 3Hospital Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Complejo Hospitalario de Navarra, Pamplona, Spain, 6Hospital Universitario de Donostia, San Sebastián, Spain, 7Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 8Hospital Sierrallana, Torrelavega, Spain, 9Hospital General Universitario de Alicante, Alicante, Spain, 10Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 11Hospital San Cecilio, Granada, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Hospital Universitario de Basurto, Bilbao, Spain, 14Hospital Universitario de Elda, Alicante, Spain, 15Hospital Universitario Juan Canalejo, A Coruña, Spain, 16Hospital Universitari Parc Tauli, Saadell, Spain, 17Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 18Hospital General Universitario Gregorio Marañón, Madrid, Spain, 19Hospital Universitario de Araba, Mondragón, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 22Hospital Clínico Universitario de Valencia, Valencia, Spain, 23Hospital Sant Pau, Barcelona, Spain, 24Hospital Vall d'Hebron, Barcelona, Spain, 25Hospital Universitario Puerta de Hierro, Madrid, Spain, 26Hospital Universitario Ramón y Cajal, Madrid, Spain, 27Hospital San Pedro, Logroño, La Rioja, Spain, 28Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, 29Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 30Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 31Hospital Universitario Salamanca, Salamanca, Spain, 32Hospital Universitario Virgen del Rocío, Sevilla, Spain, 33Complejo Hospitalario de Zamora, Zamora, Spain, 34Hospital Universitario y Politécnico La Fe, Valencia, Spain, 35Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 36Hospital Universitario Severo Ochoa, Madrid, Spain, 37Hospital General Universitario de Elche, Elche, Spain, 38Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 39Hospital de Cabueñes, Gijón, Spain, 40Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, 41Hospital San Agustín, Aviles, Spain, 42Hospital Universitario de Valme, Sevilla, Spain, 43Consorci Hospital General Universitari de Valencia, Valencia, Spain, 44Hospital Universitario Doctor Negrín, Gran Canaria, Spain, 45Hospital Universitario de Castellón, Castellón, Spain, 46Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 47Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 48Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) may be divided into cranial, and extracranial GCA phenotypes. Tocilizumab (TCZ) has shown efficacy and safety in GCA.Our aim was…
  • Abstract Number: 1864 • ACR Convergence 2021

    18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis

    Ertugrul Cagri bolek1, Kaitlin Quinn2, Hugh Alessi3, Elaine Novakovich4, Mark A. Ahlman4 and Peter Grayson5, 1Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institutes of Health, Bethesda, Maryland, 4National Institutes of Health, Bethesda, MD, 5National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Imaging modalities play an important role in the diagnosis and management of patients with large-vessel vasculitis (LVV). Use of 18F-fluorodeoxyglucose (FDG) positron emission tomography…
  • Abstract Number: 0622 • ACR Convergence 2021

    Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California

    Kathleena D'Anna and Mehrnaz Hojjati, Loma Linda University Health, Loma Linda, CA

    Background/Purpose: Giant-Cell Arteritis (GCA) is the most common systemic vasculitis among North Americans, historically described in Caucasian populations, with limited clinical data in other ethnic…
  • Abstract Number: 1406 • ACR Convergence 2021

    Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study

    Jesús T. Sánchez-Costa1, Rafael B. Melero-González2, Elisa Fernández-Fernández3, María T. Silva-Diaz4, Joaquín M. Belzunegui5, Clara Moriano6, Julio Sánchez7, Judit Lluch8, Itziar Calvo9, Vicente Aldasoro10, Lydia Abasolo11, Javier Loricera12, Alberto Ruíz-Román13, Santos Castañeda14, Patricia Moya15, María J. Garcia-Villanueva16, Vanessa A. Navarro-Angeles17, Carles Galisteo18, Anne Riveros-Frutos19, Jose A. Román-Ivorra20, Selene Labrada-Arrabal21, Margarida Vasques-Rocha22, Carlota L. Iñiguez-Ubiaga23, María García-González24, Clara Molina-Almela25, María Alcalde-Villar26, Antonio Juan Mas27, Eugenio De Miguel28, Javier Narvaez29, Miguel Ángel gonzalez-Gay30, Noemí Garrido-Puñal13, Paula V. Estrada-Alarcon17 and Ricardo Blanco31, 1Research unit, Spanish Society of Rheumatology, Madrid, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 3Rheumatology department, La Paz University Hospital, Madrid, Spain, 4Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 5Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 6Hospital Universitario de León, León, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 9Basurto University Hospital, Bilbao, Spain, 10Complejo Hospitalario de Navarra, Pamplona, Spain, 11Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, 12Hospital Universitario Marqués de Valdecilla, Santander, Spain, 13Hospital Universitario Virgen del Rocío, Sevilla, Spain, 14Hospital Universitario de la Princesa, Madrid, Spain, 15Hospital Sant Pau, Barcelona, Spain, 16Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, 17Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 18Hospital Universitari Parc Tauli, Saadell, Spain, 19Hospital Germans Trias i Pujol, Badalona, Spain, 20Hospital Universitari i Politècnic La Fe, Valencia, Spain, 21Hospital del Mar, Barcelona, Spain, 22Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 23Hospital Universitario Lucus Augusti, Lugo, Spain, 24Hospital Universitario de Canarias, La Laguna, Spain, 25Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain, 26Hospital Universitario Severo Ochoa, Leganés, Spain, 27Rheumatology Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 28Hospital Universitario La Paz, Madrid, Spain, 29Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 31Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries…
  • Abstract Number: 1867 • ACR Convergence 2021

    Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis

    Andrew Porter1, Robert Maughan1, Charis Pericleous1, Allan Kiprianos1, Hyuk Jee2, Pui Lee2, Taryn Youngstein1 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Boston Children's Hospital, Newton, MA

    Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) leads to a broad phenotype that in some resembles polyarteritis nodosa with fever and rash, but in others…
  • Abstract Number: 0652 • ACR Convergence 2021

    Application of a GCA Probability Score to Patients Referred to a GCA Fast Track Clinic

    Mmoloki Mathake1, Julia Murdoch2, Andrew Taylor3, Jean-Louis deSousa2, Kathy Jao2, Rachel Li2 and Helen Keen4, 1Fiona Stanley Hospital, Beckenham, Australia, 2Royal Perth Hospital, Perth, Australia, 3Fiona Stanley Hospital, Murdoch, Australia, 4Fiona Stanley Hospital, Perth, Australia

    Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis, and may be associated with irreversible blindness(1). It is therefore essential to make…
  • Abstract Number: 1408 • ACR Convergence 2021

    Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients

    Jesús T. Sánchez-Costa1, Iñigo Hernández-Rodríguez2, Elisa Fernández-Fernández3, María T. Silva-Diaz4, Jesús A. Valero-Jaimes5, Ismael González-Fernández6, Julio Sánchez7, Judit Lluch8, Eva Galindez-Agirregoikoa9, Javier Mendizábal-Mateos10, Pia M. Lois Bermejo11, Javier Loricera12, Alejandro Muñoz13, Cristina Valero-Martínez14, Patricia Moya15, Carmen Larena-Grijalba16, Vanessa A. Navarro-Angeles17, Joan Calvet-Fontova18, Ivette Casafont19, Francisco Ortiz-Sanjuán20, Selene Labrada-Arrabal21, Jaime Calvo-Alén22, Carlota L. Iñiguez-Ubiaga23, Vanesa Hernández24, Cristina Campos-Fernández25, María Alcalde-Villar26, Antonio Juan-Mas27, Eugenio De Miguel28, Javier Narvaez29, Miguel Ángel gonzalez-Gay30, Noemí Garrido-Puñal31, Paula V. Estrada-Alarcon17 and Ricardo Blanco32, 1Spanish Society of Rheumatology, Madrid, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 3Rheumatology department, La Paz University Hospital, Madrid, Spain, 4Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 5Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 6Hospital Universitario de León, León, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 9Hospital Universitario de Basurto, Bilbao, Spain, 10H. Navarra, Navarra, Spain, 11Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, 12Hospital Universitario Marqués de Valdecilla, Santander, Spain, 13Hospital Universitario Virgen del Rocío, Sevial, Spain, 14Hospital Universitario de La Princesa, Madrid, Spain, 15Hospital Sant Pau, Barcelona, Spain, 16Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, 17Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 18Hospital Universitari Parc Tauli, Sabadell, Spain, 19Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, 20H. La Fe, Valencia, Spain, 21Hospital del Mar, Barcelona, Spain, 22Rheumatology Department, Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 23Hospital Universitario Lucus Augusti, Lugo, Spain, 24Rheumatology Department, Hospital Universitario de Canarias, La Laguna, Spain, 25Consorci Hospital General Universitari de Valencia, Valencia, Spain, 26Hospital Universitario Severo Ochoa, Leganés, Spain, 27Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 28Hospital Universitario La Paz, Madrid, Spain, 29Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 30Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 31Hospital Universitario Virgen del Rocío, Sevilla, Spain, 32Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology